Clinical trials: TEN
Asthma
Bronchial Thermoplasty 10+ Year Study
To confirm the long-term efficacy and safety of Bronchial Thermoplasty (BT) at 10 years follow-up or beyond in subjects previously enrolled in any of the following Boston Scientific-sponsored, controlled pre-approval studies…
- Trial name
- NCT03243292
- Testing
- Bronchial Thermoplasty
- Where
- 17 sites in United States, Brazil and 3 more
- Volunteers
- 192 people
- Sponsor
- Boston Scientific Corporation
Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis
Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.
Patients diagnosed with Stevens-Johnson syndrome and Toxic Epidermal Necrolysis were confirmed based on the investigators national diagnostic criteria.
- Trial name
- NCT01696500
- Testing
- Intravenous immunoglobulin
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Nihon Pharmaceutical Co., Ltd
Depressive Disorder
MDD POC Study GSK372475 Subjects Depressive Disease
To evaluate the efficacy, safety and tolerability of GSK372475 compared with placebo in the treatment of outpatients subjects with major depressive disorder to exhibit decreased pleasure, interest and energy.
- Trial name
- NCT00420641
- Testing
- GSK372475, Paroxetine
- Where
- 33 sites in Bulgaria, Canada and 8 more
- Volunteers
- 492 people
- Sponsor
- GlaxoSmithKline
Nicotine Dependence, Nicotine Dependence, Cigarettes
Comparing the Pharmacokinetics of Nicotine Salt Based ENDS in Healthy Smokers
A Ten Sequence, Open Label, Randomized Crossover Study Comparing Nicotine Pharmacokinetics of JUUL 1.7% and JUUL 5% Nicotine Salt Based ENDS Products, in Healthy Adult Smokers.
- Conditions
- Nicotine Dependence, Nicotine Dependence, Cigarettes, Tobacco Use, Tobacco Smoking
- Trial name
- NCT03593239
- Testing
- Tobacco flavored JUUL 1.7% ENDS, Tobacco flavored JUUL 5% ENDS, Mint flavored JUUL 1.7% ENDS
- Where
- New Zealand
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Juul Labs, Inc.